Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. Craig JW, Mina MJ, Crombie JL, et al. Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS One. 2018;13(7):e0199708. doi:10.1371/journal.pone.0199708 Read more